Peptide Immunogenicity: Why Small Molecules Can Still Trigger Immune Responses

Size lowers risk but does not eliminate it

Short peptides may contain T-cell epitopes, bind to carrier proteins, aggregate, or form structures that are more visible to the immune system. Repeated exposure can increase opportunity for sensitization.

Impurities can be immunologically relevant

Deletion sequences, insertion sequences, oxidized variants, racemized residues, aggregates, and process contaminants may alter uptake and antigen presentation. Two products with the same labeled sequence can have different impurity profiles.

Route and formulation matter

Subcutaneous or intramuscular exposure can create different immune conditions than oral or intravenous delivery. Adjuvant-like excipients, particles, or contaminants may amplify responses.

Consequences vary

Anti-drug antibodies may have no measurable effect, reduce activity, change clearance, trigger hypersensitivity, or cross-react with an endogenous peptide. Clinical relevance requires direct evaluation.

Prediction has limits

In silico epitope tools and preclinical assays can identify risks, but human immune diversity and product-specific factors prevent perfect prediction.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.